Antibody therapy

Hundreds of People at Risk for Severe COVID-19 Avoid Hospitalization with New Treatment

Retrieved on: 
Thursday, February 18, 2021
Medical specialties, Immunology, Clinical medicine, Medicine, Monoclonal antibodies, Antibodies, Glycoproteins, Human anti-mouse antibody, Antibody therapy

After her positive test, she arrived at Montefiore Medical Center to begin monoclonal antibody treatment.

Key Points: 
  • After her positive test, she arrived at Montefiore Medical Center to begin monoclonal antibody treatment.
  • Monoclonal antibodies are created in a lab and function like naturally occurring antibodies, fighting infections before they spread.
  • "Now Bronx residents have a safe, evidence-based treatment that stops COVID-19 in its tracks and is preventing severe illness."
  • The monoclonal antibody treatment is given using IV therapy, administered through a vein in the arm, for about an hour.

Monoclonal Antibody Treatment Available for Chelsea Residents

Retrieved on: 
Tuesday, February 2, 2021
Medical specialties, Health sciences, Medicine, Immunology, Monoclonal antibody, Coronavirus disease, Antibody therapy, Therapy

FANWOOD, N.J., Feb. 2, 2021 /PRNewswire/ -- Chelsea Senior Living will be among the first assisted living companies in New Jersey to make on-site monoclonal antibody treatments available to residents symptomatic with COVID-19.

Key Points: 
  • FANWOOD, N.J., Feb. 2, 2021 /PRNewswire/ -- Chelsea Senior Living will be among the first assisted living companies in New Jersey to make on-site monoclonal antibody treatments available to residents symptomatic with COVID-19.
  • This allows the affected residents to avoid a hospital trip while receiving a treatment that has been effective in reducing symptoms.
  • Monoclonal antibody therapy, given by infusion, is not a cure for COVID-19 and is not a substitute for the vaccine.
  • "The impact the monoclonal antibody (mAb) has had on our patients has been nothing short of remarkable," said John Hopkins, DO, CCS Healthcare.

Abpro Announces Positive Phase 1 Results Demonstrating A Favorable Safety and Pharmacokinetic Profile of ABP 300, A Neutralizing Antibody Therapeutic for the Treatment of COVID-19

Retrieved on: 
Tuesday, February 2, 2021
Medical specialties, Clinical medicine, Medicine, Immune system, Biotechnology, Immunology, Monoclonal antibody, Coronavirus disease, Neutralizing antibody, Antibody therapy

The Phase 1 clinical trial was conducted in 42 healthy subjects and showed safety and pharmacokinetic data at doses from 4 mg/kg to 60 mg/kg.

Key Points: 
  • The Phase 1 clinical trial was conducted in 42 healthy subjects and showed safety and pharmacokinetic data at doses from 4 mg/kg to 60 mg/kg.
  • Following the completion of this Phase 1 in December 2020, a series of Phase 2/3 registrational studies of ABP 300 has recently been initiated.
  • Completion of this safety study in December stands as an encouraging validation of this potentially best-in-class therapy.
  • ABP 300 is a human neutralizing monoclonal antibody therapy against COVID-19thatwascreated using the latest technologies available for antibody discovery.

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Retrieved on: 
Wednesday, September 16, 2020
Medical specialties, Medicine, Branches of biology, Immunology, Coronavirus disease, Occupational safety and health, Zoonoses, AbCellera, Neutralizing antibody, Antibody therapy, Antibody, COVID-19 drug repurposing research

The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555, a SARS-CoV-2-neutralizing antibody, for the treatment of symptomatic COVID-19 in the outpatient setting.

Key Points: 
  • The randomized, double-blind, placebo-controlled Phase 2 study evaluated LY-CoV555, a SARS-CoV-2-neutralizing antibody, for the treatment of symptomatic COVID-19 in the outpatient setting.
  • These biomarker data correlated with LY-CoV555s positive impact on the prespecified endpoint of COVID-19-related hospitalization or ER visit.
  • LY-CoV555 emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.
  • Lilly intends to test both single-antibody therapy as well as combinations of antibodies (sometimes known as antibody cocktails) as potential therapeutics for COVID-19.

Monoclonal Antibody Therapy Drug Market on Trajectory Towards $140 Billion

Retrieved on: 
Thursday, April 4, 2019
Immune system, Immunology, Branches of biology, Biology, Life sciences, Monoclonal antibodies, Antibody therapy, Antibody

Potentially incentivized by a new study on the monoclonal antibody therapy market, analysts recently projected a double-digit 10.5% CAGR by 2022, and revenues to touch $140 billion.

Key Points: 
  • Potentially incentivized by a new study on the monoclonal antibody therapy market, analysts recently projected a double-digit 10.5% CAGR by 2022, and revenues to touch $140 billion.
  • Using proprietary antibody discovery platforms and innovative technologies, Talem will be producing a rich pipeline of high quality and distinct antibodies.
  • Domestically, the US drug industry spends approximately $45 billion annually on research and development (R&D).
  • While the antibody discovery CRO segment topped over US$100 billion in 2017 , it's projected to grow to US$125 billion by 2020 .

Monoclonal Antibody Therapy Drug Market on Trajectory Towards $140 Billion

Retrieved on: 
Thursday, April 4, 2019
Immune system, Immunology, Branches of biology, Biology, Life sciences, Monoclonal antibodies, Antibody therapy, Antibody

Potentially incentivized by a new study on the monoclonal antibody therapy market, analysts recently projected a double-digit 10.5% CAGR by 2022, and revenues to touch $140 billion.

Key Points: 
  • Potentially incentivized by a new study on the monoclonal antibody therapy market, analysts recently projected a double-digit 10.5% CAGR by 2022, and revenues to touch $140 billion.
  • Using proprietary antibody discovery platforms and innovative technologies, Talem will be producing a rich pipeline of high quality and distinct antibodies.
  • Domestically, the US drug industry spends approximately $45 billion annually on research and development (R&D).
  • While the antibody discovery CRO segment topped over US$100 billion in 2017 , it's projected to grow to US$125 billion by 2020 .